Adaptimmune Inks Lucrative Deal for Cancer Therapy Trial
Company Announcements

Adaptimmune Inks Lucrative Deal for Cancer Therapy Trial

Adaptimmune Therapeutics (ADAP) has issued an announcement.

Adaptimmune Limited and Galapagos NV have embarked on a promising collaboration, initiating a clinical trial to test a novel T-cell therapy for head & neck cancer. The agreement nets Adaptimmune $70 million upfront plus potential milestone payments up to $465 million and royalties on future sales. While Galapagos gains exclusive licensing options, Adaptimmune retains rights for its therapy in treating ovarian cancer. This strategic partnership could revolutionize cancer treatment and offers financial upside for both companies.

For detailed information about ADAP stock, go to TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskAdaptimmune Enhances Severance Benefits for Executives
TipRanks Auto-Generated NewsdeskAdaptimmune Enhances Executive Severance and Benefit Terms
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!